Prioritising drugs for single patient (n-of-1) trials in palliative care
Prioritising drugs for single patient (n-of-1) trials in palliative care
复制标题
姑息治疗中单个患者（n-of-1）试验的优先药物
作者：
J. Nikles;Geoffrey Mitchell;Julie Walters;Janet Hardy;Phillip Good;Debra Rowett;Tania Shelby;David C. Currow
姑息治疗患者常用的许多药物都有潜在的严重副作用，而且没有得到证实的益处。获得证据来支持这些药物的处方一直非常缓慢。单患者试验（spt）（也称为n-of-1试验）提供了一种潜在的手段，可以获得必要的证据，以支持或反驳目前仅基于医生经验或轶事的几种药物和干预措施的使用。在姑息治疗中，对于常用的治疗方法和最常见和最棘手的症状，提出了一份被认为是“最紧急”的spt清单。对于这些药物，证据和实践之间的差距最大，最缺乏疗效证据，严重的副作用可能导致最高的发病率，或者费用是患者的主要负担。虽然并非所有用于姑息治疗的药物都适用，但spt为姑息治疗提供了一种潜在的替代性证据收集方法。
Many of the drugs prescribed commonly to palliative care patients have potentially significant side-effects and are of unproven benefit. The acquisition of evidence to support the prescribing of these drugs has been very slow. Single patient trials (SPTs) (also known as n-of-1 trials) offer a potential means of obtaining the evidence necessary to support or refute the use of several of the drugs and interventions whose use is currently based on physician experience or anecdote alone. A list of SPTs considered “most urgent”, for commonly employed treatments and for the most common and most troublesome symptoms in palliative care is presented. These are drugs for which the gap between evidence and practice is greatest, where the evidence of efficacy is most lacking, where significant side effects potentially lead to the greatest morbidity, or where cost is a major patient burden. Although not all the drugs used in palliative care are suitable, SPTs provide a potential alternative method of gathering evidence in palliative care.
影响因子：
7.2
作者：
Zucker, DR;Schmid, CH;Lau, J
通讯作者：
Lau, J